Scholarlink

<p>Silk-derived sericin exhibits inherent antioxidant, antibacterial, and anticancer properties, but it faces limitations due to instability and rapid degradation in physiological environments. To address these challenges, bioinspired sericin-polycaprolactone nanoparticles (SS-PCL NP) were synthesized using a double-emulsion solvent-evaporation method, with Pluronic F68 serving as a stabilizer. The optimized nanoparticles exhibited a uniform spherical morphology with average size of 73.4 ± 14.8&#xa0;nm, high encapsulation efficiency (≈ 85%), and pH-responsive sustained release, achieving ≈ approximately 99% cumulative release within 24–48&#xa0;h under acidic conditions. Spectroscopic and microscopic analyses (FTIR, XRD, NMR, FESEM, etc.) confirmed successful encapsulation and intermolecular compatibility between sericin and PCL. The SS-PCL nanoparticles demonstrated enhanced antioxidant potential (IC₅₀ ≈ 48&#xa0;µg/mL) compared to free sericin, and exerted selective cytotoxicity against cancer cells; MCF-7 (IC₅₀ ≈ 3.5&#xa0;µg/mL) and A549 (IC₅₀ ≈ 49.5&#xa0;µg/mL) with minimal toxicity toward normal human fibroblasts (IC₅₀ ≈ &gt; 1000&#xa0;µg/mL), indicating excellent biocompatibility. Additionally, the nanoparticles retained and improved antibacterial efficacy against <i>Escherichia coli</i>, <i>Staphylococcus aureus</i>, and <i>Klebsiella pneumoniae</i>, with minimum inhibitory concentration (MICs) of 125&#xa0;µg/mL and 15.6&#xa0;µg/mL, respectively. The results highlight a synergistic system combining sericin’s bioactivity with PCL’s sustained-release characteristics, offering a promising strategy for multifunctional nanotherapeutics in cancer management while mitigating infection-associated complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bioinspired Sericin-PCL Nanoparticles for Sustained Delivery in Cancer with Antioxidant and Antibacterial Efficacies

  • 期刊论文

  • 发表日期：

    2026年2月16日

查看全文
  • Monal S. Salvi,
  • Sachin B. Agawane

摘要

Silk-derived sericin exhibits inherent antioxidant, antibacterial, and anticancer properties, but it faces limitations due to instability and rapid degradation in physiological environments. To address these challenges, bioinspired sericin-polycaprolactone nanoparticles (SS-PCL NP) were synthesized using a double-emulsion solvent-evaporation method, with Pluronic F68 serving as a stabilizer. The optimized nanoparticles exhibited a uniform spherical morphology with average size of 73.4 ± 14.8 nm, high encapsulation efficiency (≈ 85%), and pH-responsive sustained release, achieving ≈ approximately 99% cumulative release within 24–48 h under acidic conditions. Spectroscopic and microscopic analyses (FTIR, XRD, NMR, FESEM, etc.) confirmed successful encapsulation and intermolecular compatibility between sericin and PCL. The SS-PCL nanoparticles demonstrated enhanced antioxidant potential (IC₅₀ ≈ 48 µg/mL) compared to free sericin, and exerted selective cytotoxicity against cancer cells; MCF-7 (IC₅₀ ≈ 3.5 µg/mL) and A549 (IC₅₀ ≈ 49.5 µg/mL) with minimal toxicity toward normal human fibroblasts (IC₅₀ ≈ > 1000 µg/mL), indicating excellent biocompatibility. Additionally, the nanoparticles retained and improved antibacterial efficacy against Escherichia coli, Staphylococcus aureus, and Klebsiella pneumoniae, with minimum inhibitory concentration (MICs) of 125 µg/mL and 15.6 µg/mL, respectively. The results highlight a synergistic system combining sericin’s bioactivity with PCL’s sustained-release characteristics, offering a promising strategy for multifunctional nanotherapeutics in cancer management while mitigating infection-associated complications.